RECRUITINGOBSERVATIONAL
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
About This Trial
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of Multiple sclerosis (MS)
- Currently or recently pregnant
- Reside in the United States, Canada or Germany.
Who Should NOT Join This Trial:
• Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester.
Other protocol-defined inclusion/exclusion criteria apply
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of Multiple sclerosis (MS)
* Currently or recently pregnant
* Reside in the United States, Canada or Germany.
Exclusion Criteria:
• Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester.
Other protocol-defined inclusion/exclusion criteria apply
Locations (3)
Evidera INC.
Bethesda, Maryland, United States
Evidera
Bethesda, Maryland, United States
Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum
Herne, Germany